Table 4 Studies comparing clinical outcomes and radiotherapy-related toxicities in patients with OAL treated with ultra-low-dose radiotherapy
From: Ultra-low-dose radiotherapy in the treatment of ocular adnexal lymphoma: a prospective study
Study, year (ref) | Clinical characteristics | Treatment | Number of study patients | Disease outcome at follow-up | Type(s) of side effects | No. of patients with side effects | |
|---|---|---|---|---|---|---|---|
Partial response (PR) rate | complete response (CR) rate | ||||||
[14] | Indolent non-Hodgkin lymphoma (NHL) of the ocular adnexa | 2 fractions of 2 Gy | 20 | 11% | 85% | Dry eye | 1 |
Acute conjunctivitis | 1 | ||||||
Transient periorbital edema | 4 | ||||||
[15] | Indolent orbital lymphomas | 2 fractions of 2 Gy | 7 | 0% | 100% | Xerophthalmia | 1 |
[20] | B-cell ocular adnexal lymphoma | 2 fractions of 2 Gy | 22 | 14% | 86% | Dry eye | 1 |
This study | Ocular adnexal low-grade non-Hodgkin lymphoma | 2 fractions of 2 Gy | 16 | 13% | 75% | none | none |